Provided by Tiger Fintech (Singapore) Pte. Ltd.

NKGEN BIOTECH INC

0.2600
+0.068735.91%
Post-market: 0.26010.0001+0.04%16:00 EST
Volume:1.56M
Turnover:290.18K
Market Cap:11.69M
PE:-0.06
High:0.2700
Open:0.1210
Low:0.1020
Close:0.1913
Loading ...

NKGen Biotech - Co's Inability to Pay Its Payroll Obligations May Result in Employees Terminating Relationship With Co and/or Pursuing Legal Remedies

THOMSON REUTERS
·
31 Oct 2024

NKGen Biotech Inc - on Oct 24, Co Placed 19 Employees on Furlough, Effective October 27

THOMSON REUTERS
·
31 Oct 2024

NKGen Biotech announces presentation of two posters in AD

TIPRANKS
·
29 Oct 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS
·
29 Oct 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

GlobeNewswire
·
29 Oct 2024

NKGen Biotech Announces Poster Presentations at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS
·
08 Oct 2024

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

GlobeNewswire
·
08 Oct 2024

BRIEF-Nkgen Biotech Size Of Board Temporarily Reduced From Five To Two Directors

Reuters
·
04 Oct 2024

NKGen Biotech: Size of Each Committee Is Temporarily Reduced From Three to One Member

THOMSON REUTERS
·
04 Oct 2024

BRIEF-NKGen Biotech Receives Deficiency Letter From Nasdaq

Reuters
·
28 Sep 2024

NKGen Biotech Inc -on Sept 23, Got Deficiency Letter From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard

THOMSON REUTERS
·
28 Sep 2024

NKGen Biotech Inc - No Drug-Related Adverse Reactions in Phase 1 Cohort After 3 Months

THOMSON REUTERS
·
12 Sep 2024

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel Into Phase 2 With First Patient Dosed in Phase 1/2a Trial

THOMSON REUTERS
·
12 Sep 2024

NKGen Biotech Inc - Two Phase 1 Patients Show Improved Cognitive Scores After 3 Months

THOMSON REUTERS
·
12 Sep 2024

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

GlobeNewswire
·
12 Sep 2024